Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/301244 
Erscheinungsjahr: 
2024
Schriftenreihe/Nr.: 
Research Paper No. 204
Verlag: 
South Centre, Geneva
Zusammenfassung: 
This paper analyzes the debate over the international dissemination of data exclusivity as a form of protection for clinical trial data. This is a critical demand for pharmaceutical companies seeking larger market shares and longer periods of monopoly in order to recover investments in research and development and greater profitability. However, this is a sensitive issue with economic and social repercussions for developing countries that adopt this protection regime. This paper highlights critical issues for the political economy of innovation and presents a review of empirical studies that show that data exclusivity delays the entry of generic drugs into the market, increasing prices and reducing access. At the same time, its adoption has no benefits because there are no positive effects on internal technological innovation, nor reduction of the "International drug lag", nor the development of drugs for specific epidemiological demands.
Schlagwörter: 
Access to Medicines
Clinical Trials
Data Exclusivity
Generic Medicines
Health
Healthcare
Innovation
Intellectual Property
Pharmaceuticals
Research and Development (R&D)
Test Data
Test Data Protection
TRIPS
TRIPS Agreement
Dokumentart: 
Research Report
Erscheint in der Sammlung:

Datei(en):
Datei
Größe
4.82 MB





Publikationen in EconStor sind urheberrechtlich geschützt.